Our determination to find answers for patients and their families motivates us to pursue medicines and vaccines with the greatest potential to improve lives and protect public health. With a strong focus on difficult-to-treat diseases and immunization, our R&D pipeline includes clinical-stage projects, of which are in phase 3 or have been submitted to regulatory authorities for approval. Some of these are new molecular entities while others are existing products with potential new indications, or different formulations. All of them are made possible by people who volunteer to participate in a clinical trial.
This page was updated on March 31, 2022
You can search or browse our R&D pipeline by therapeutic area, study phase, indication, or technology. Click on a candidate to see more details. We shared the latest updates to our pipeline at the Q1 2022 Results Meeting, which took place on April 28, 2022. The brand names you see here are trademarks either owned by or licensed to Sanofi or associated companies. The safety and efficacy of these investigational agents have not been established.
Expected submission timelines
Expected R&D milestones